1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Renalytix Plc

Renalytix Plc

RENX.L
Renalytix PlcGB flagLondon Stock Exchange
2.75
GBp
+0.05
- -
10.08MMarket Cap
Renalytix Plc
RENX.L
(London Stock Exchange)

Recent

price

2.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.02
0.04
0.04
0.02
0.01
0.02
Revenue per Share
- -
-1.13
-0.17
-0.43
-0.62
-0.55
-0.42
-0.07
-0.23
Basic EPS, GAAP
- -
-0.47
-0.18
-0.37
-0.64
-0.41
-0.28
-0.07
-0.23
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-1.14
0.59
0.06
-1.82
-2.17
-1.33
-0.6
-1.5
Book Value per Share
- -
-0.26
0.32
1.08
0.23
0.08
-0.08
-0.03
-0.01
Tangible Book Value per Share
- -
37
59
71
73
82
108
275
102
Basic Weighted Avg Shares
- -
- -
- -
1
3
3
2
3
2
Sales/Revenue/Turnover
- -
- -
- -
-2,187.19
-1,790.67
-1,240.7
-1,326.09
-573.33
-807.29
Operating Margin (%)
- -
- -
- -
2
- -
1
2
- -
-1
Depreciation Expense
- -
-42
-10
-31
-45
-46
-46
-20
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-2,079.81
-1,524.44
-1,340.2
-1,978.26
-680
-987.65
Profit Margin (%)
-1
8
16
69
33
11
-5
1
7
Working Capital
- -
- -
- -
- -
8
8
4
8
8
LT Debt
-1
9
36
95
31
7
-9
-7
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-158.83
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'25
Dec'25
ST Debt
4
4
- -
LT Borrowings
4
4
8
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
154
166
331
Market Capitalization
1,338
1,088
1,368

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'25
Dec'25
Total Current Assets
7
3
11
Cash, Cash Equivalents & STI
5
1
10
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
12
12
5
Payables & Accruals
- -
- -
- -
ST Debt
4
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-46.4%
-22.22%
Free Cash Flow
- -
28.46%
-39.94%
Net Income, GAAP
- -
41.27%
-55.16%
Sales/Revenue/Turnover
- -
- -
30.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
1
1
2
2025
1
1
- -
- -
3
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.11
- -
-0.08
- -
-0.42
2025
-0.04
- -
- -
- -
-0.07
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Surgical Science Sweden AB (publ) (SUS.ST)
HITIQ Limited (HIQ.AX)
Rocket Doctor AI Inc. (AIDR.CN)
PainChek Limited (PCK.AX)
Sensyne Health plc (SENS.L)
M3, Inc. (MTHRY)
Business
Renalytix Plc is a United Kingdom-based precision medicine company specializing in the development of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its core product, KidneyIntelX, is a machine learning-powered prognostic platform that combines blood-based biomarkers, inherited genetics, and personalized patient electronic health record data to generate early-stage chronic kidney disease progression risk assessments. KidneyIntelX is FDA-approved and Medicare reimbursed, designed to improve kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's offerings focus on addressing diabetic kidney disease and broader chronic kidney disease populations through advanced bioprognostic technology across the United States and Europe. Founded in 2018 and headquartered in London, Renalytix engages primarily in the health care technology and diagnostics sectors, targeting healthcare providers, pharmaceutical companies, and clinical research organizations. Its services support more effective clinical decision-making and aim to mitigate the progression of kidney disease through precision early diagnostics. Recent major company developments include a strategic collaboration agreement signed in September 2025 with Tempus AI, Inc., to expand access to its KidneyIntelX.dkd prognostic blood test within U.S. healthcare networks and integrate the test into Tempus' portfolio of clinical diagnostic offerings. This partnership is expected to enhance patient and clinician access to precision medicine diagnostics for chronic kidney disease and foster innovation through multi-modal data analysis across cardiovascular, renal, and metabolic disease areas. Additionally, in 2025, Renalytix formed a partnership with MVP Health Care to increase patient access to kidney disease testing for individuals with diabetic kidney disease in the U.S. Renalytix continues to build its intellectual property portfolio and explores opportunities for in-licensing technologies to bolster its diagnostic platform. The company’s operations are focused mainly in the United States, with its corporate headquarters located in London, UK.

Company News

APIChatGPT

  • defenseworld.net

    Renalytix (LON:RENX) Trading Down 1.7% – What’s Next?